With the goal of developing innovative drugs on a global scale, Oneness Biotech has established a value chain for the research and development of new drugs independently, namely R (research), D (development), C (clinical), and M (Marketing). This includes the professional R&D teams and technologies for different domains such as the establishment of a technology platform, CMC (chemistry, manufacturing, and controls), pharmacology/toxicology, pharmacokinetics/toxicokinetics, clinical pharmacology/pharmacokinetics, and clinical medicine.

Oneness is keen on employment training, new drug development and innovation of technology. Our pipelines cover Phases I, II, III, NDA and approval phases. With strong R&D team and capability for new drugs, we have set up raw material cultivation bases, API and finished dosage manufacturing plant according to GACP and PIC/S GMP standards for botanical drugs. The streamlined control ensures the effectiveness, safety, and consistency of our drug quality. Besides, we have developed antibody new drugs for severe asthma, atopic dermatitis, and other indications based on the established proprietary technologies including fully-human antibody library, a high-performance screening platform, a stable and high-yield antibody-producing cell line, and a cancer stem cell platform. With the first approved new drug: Fespixon (for DFUs), Oneness dedicates its R&D efforts to chronic dermatological and immunological disorders. Through licensing or co-development, Oneness can provide patients with cost-effective treatments and achieve our founding mission of ""developing new drugs and caring for life"".